Skip to Main Content

Editors Choice

1 Results

Original Article Non–Small Cell Lung Cancer
Open Archive
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Journal of Thoracic Oncology
Vol. 12Issue 12p1798–1805Published online: September 19, 2017
- Shunsuke Teraoka
- Daichi Fujimoto
- Takeshi Morimoto
- Hayato Kawachi
- Munehiro Ito
- Yuki Sato
- and others
Cited in Scopus: 263
Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy.